Page last updated: 2024-10-25

citalopram and Cardiovascular Diseases

citalopram has been researched along with Cardiovascular Diseases in 13 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"The DECARD (DEpression in patients with Coronary ARtery Disease) trial assessed the prophylactic effect of escitalopram on depression after ACS."9.16Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. ( Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Nielsen, OW; Rasmussen, A, 2012)
"The DECARD (DEpression in patients with Coronary ARtery Disease) trial assessed the prophylactic effect of escitalopram on depression after ACS."5.16Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. ( Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Nielsen, OW; Rasmussen, A, 2012)
" To compare the effects of antidepressant drugs, the electrocardiogram (ECG), vectorcardiogram (VCG), and body surface maps (BSM) were recorded in psychiatric patients without cardiovascular diseases treated by a) TCA amitriptyline or dosulepin (daily dose 50-200 mg, 22 patients), b) lithium (serum level 0."3.70Antidepressant drugs and heart electrical field. ( Hamplová, J; Horácek, BM; Kittnar, O; Paclt, I; Slavícek, J; Trefný, Z, 1998)
"We investigated whether treating depression in older participants impacted on arterial stiffness, a known cardiovascular disease risk factor and a clinical marker of arterial aging."2.78Depression treatment selectively modifies arterial stiffness in older participants. ( Assisi, AP; Fedullo, F; Gianni, W; Modestino, A; Scuteri, A, 2013)
"Escitalopram (n=3298) was administered at doses between 5 and 20mg/day."1.39The cardiovascular safety profile of escitalopram. ( Kennedy, SH; Larsen, KG; Reines, E; Thase, ME, 2013)
" The aim of this study was to investigate the toxic effects and toxicokinetic parameters of citalopram in an overdose as a single drug and in combination with other drugs."1.35Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. ( Caminada, K; Hunfeld, NG; Jimmink, A; Touw, DJ, 2008)
"The aim of the present study was to compare cardiovascular and/or cardiotoxic effects of eight anti-depressants (imipramine, chlorimipramine, amitriptyline, nortriptyline , doxepin, maprotiline, mianserin and citalopram) in anaesthetized cats after oral dosing and in conscious rabbits after intravenous infusion."1.27Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels. ( Boeck, V; Fredricson Overø, K; Jørgensen, A, 1984)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19901 (7.69)18.7374
1990's1 (7.69)18.2507
2000's3 (23.08)29.6817
2010's8 (61.54)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wu, WT1
Tsai, CT1
Chou, YC1
Ku, PM1
Chen, YC1
You, SL1
Hung, CF1
Sun, CA1
Gerlach, LB1
Kim, HM1
Yosef, M1
Kales, HC1
Henry, J1
Zivin, K1
Guo, S1
Chen, L1
Cheng, S1
Xu, H1
Thase, ME1
Larsen, KG1
Reines, E1
Kennedy, SH1
Jimmink, A1
Caminada, K1
Hunfeld, NG1
Touw, DJ1
Kamarck, TW1
Haskett, RF1
Muldoon, M1
Flory, JD1
Anderson, B1
Bies, R1
Pollock, B1
Manuck, SB1
Jiang, W1
Velazquez, EJ1
Samad, Z1
Kuchibhatla, M1
Martsberger, C1
Rogers, J1
Williams, R1
Kuhn, C1
Ortel, TL1
Becker, RC1
Pristera, N1
Krishnan, R1
O'Connor, CM1
Hanash, JA1
Hansen, BH1
Hansen, JF1
Nielsen, OW1
Rasmussen, A1
Birket-Smith, M1
Thombs, BD1
Scuteri, A1
Modestino, A1
Fedullo, F1
Assisi, AP1
Gianni, W1
de Jonge, P1
Honig, A1
van Melle, JP1
Schene, AH1
Kuyper, AM1
Tulner, D1
Schins, A1
Ormel, J1
Boeck, V1
Jørgensen, A1
Fredricson Overø, K1
Slavícek, J1
Paclt, I1
Hamplová, J1
Kittnar, O1
Trefný, Z1
Horácek, BM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)[NCT00574847]Phase 4127 participants (Actual)Interventional2006-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

5HTT, Serotonin Transporter Protein

End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: week 6

Interventionfmol/mg (Mean)
Escitalopram139.7
Placebo160.4

Beck Depression Inventory

The Beck Depression Inventory II (BDI-II) is a 21 question, self-administered measure of depressive symptoms. Score range, 0 to 63 (higher score=greater severity of depressive symptoms). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week

Interventionunits on a scale (Mean)
Escitalopram7.4
Placebo7.0

Cook-Medley Hostility (Ho) Hostile Affect Sub-scale

hostile affect, 0 to 5 (higher score=greater levels of hostile affect). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Escitalopram1.6
Placebo1.8

Cook-Medley Hostility (Ho) Scale

Score ranges: hostility, 0 to 27 (higher score=greater levels of hostility)/ End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Escitalopram9.9
Placebo10.3

Exercise Stressed-induced Myocardial Ischemia (ESIMI)

End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week

Interventionpercentage of change (Number)
Escitalopram45.8
Placebo52.5

Mental Stress Induced Change in Heart Rate

"A standard 12-lead Electrocardiograph (ECG) will be recorded at 1-minute intervals during the last 3 minutes of each rest period, the 3 minutes of the mental stress testing, and during exercise testing. Heart rate will be determined from the ECGs.~Mental Stress Induced Change in heart rate will be calculated by taking the mean of the mental stress heart rate measurements minus the resting heart rate measurements. End point values adjusted for baseline values age and sex." (NCT00574847)
Timeframe: baseline, 6 weeks

Interventionbeats/minute (Mean)
Escitalopram6.34
Placebo9.1

Mental Stress Induced Change of Diastolic Blood Pressure

Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Diastolic Blood Pressure will be calculated by taking the mean of the mental stress Diastolic blood pressure measurements minus the resting Diastolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6

Interventionmm Hg (Mean)
Escitalopram11.4
Placebo12.2

Mental Stress Induced Change of Systolic Blood Pressure

Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Systolic Blood Pressure will be calculated by taking the mean of the mental stress systolic blood pressure measurements minus the resting Systolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6

Interventionmm Hg (Mean)
Escitalopram19.3
Placebo23.6

Perceived Stress Scale

Score range, 10 to 50 (higher score = greater levels of perceived stress). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Escitalopram21.4
Placebo21.8

Percentage of Participants With Adverse Events

(NCT00574847)
Timeframe: Baseline to week 6

Interventionpercentage of participants (Number)
Escitalopram71.9
Placebo44.4

Percentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors

MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: Week 6

Interventionpercentage of participants (Number)
Escitalopram34.2
Placebo17.5

Percentage of Participants With Overall Mental Stress-induced Myocardial Ischemia (MSIMI)

MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: week 6

Interventionpercentage of participants (Number)
Escitalopram66.1
Placebo83.9

Platelet Serotonin Binding Affinity Kd_100

End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

InterventionnM (Mean)
Escitalopram4202.4
Placebo210.1

Spielberger State-Trait Anxiety Inventory Scales (STAI)

STAI measures anxiety. The questionnaire asks the patients how they feel and allows them to respond on a frequency scale that ranges from 1(not at all) to 4(almost always/very much so). Scores range from 20-80 and the higher the score the greater the anxiety level. This applies to both the Trait and State scales. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

,
Interventionunits on a scale (Mean)
TraitState
Escitalopram31.227.9
Placebo32.029.5

Reviews

1 review available for citalopram and Cardiovascular Diseases

ArticleYear
Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials.
    Medicine, 2019, Volume: 98, Issue:22

    Topics: Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Cardiovascular Diseases; China; Citalo

2019

Trials

5 trials available for citalopram and Cardiovascular Diseases

ArticleYear
Citalopram intervention for hostility: results of a randomized clinical trial.
    Journal of consulting and clinical psychology, 2009, Volume: 77, Issue:1

    Topics: Adult; Aggression; Cardiovascular Diseases; Citalopram; Drug Administration Schedule; Female; Hostil

2009
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
    American heart journal, 2012, Volume: 163, Issue:1

    Topics: Adult; Cardiovascular Diseases; Citalopram; Depressive Disorder; Exercise Test; Humans; Myocardial I

2012
Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.
    Journal of cardiovascular pharmacology, 2012, Volume: 60, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Citalopram; Depression; Double-Blind Method;

2012
Depression treatment selectively modifies arterial stiffness in older participants.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2013, Volume: 68, Issue:6

    Topics: Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Pressure; Cardio

2013
Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events.
    The American journal of psychiatry, 2007, Volume: 164, Issue:9

    Topics: Antidepressive Agents; Cardiovascular Diseases; Cause of Death; Citalopram; Comorbidity; Depressive

2007

Other Studies

7 other studies available for citalopram and Cardiovascular Diseases

ArticleYear
Cardiovascular Outcomes Associated With Clinical Use of Citalopram and Omeprazole: A Nationwide Population-Based Cohort Study.
    Journal of the American Heart Association, 2019, 10-15, Volume: 8, Issue:20

    Topics: Cardiovascular Diseases; Citalopram; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Foll

2019
Electrocardiogram Monitoring After the Food and Drug Administration Warnings for Citalopram: Unheeded Alerts?
    Journal of the American Geriatrics Society, 2018, Volume: 66, Issue:8

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Citalopram; Drug Monitoring; Electrocardiography;

2018
The cardiovascular safety profile of escitalopram.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:11

    Topics: Adult; Aging; Blood Pressure; Cardiovascular Diseases; Citalopram; Electrocardiography; Female; Hear

2013
Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases.
    Therapeutic drug monitoring, 2008, Volume: 30, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Central Nervous System Diseases

2008
Clarification of the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment (REMIT) trial protocol.
    American heart journal, 2012, Volume: 164, Issue:5

    Topics: Cardiovascular Diseases; Citalopram; Depressive Disorder; Humans; Selective Serotonin Reuptake Inhib

2012
Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels.
    Psychopharmacology, 1984, Volume: 82, Issue:4

    Topics: Anesthesia; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cardiac Output; Cardio

1984
Antidepressant drugs and heart electrical field.
    Physiological research, 1998, Volume: 47, Issue:4

    Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cardiovascular Diseas

1998